abstract: OBJECTIVE: @entity5042 is the most common complication after colectomy with ileal pouch-anal @entity254 (IPAA) for UC and the risk is the highest within the 1st year after surgery. The pathogenesis is not completely understood but clinical response to antibiotics suggests a role for gut microbiota. We hypothesised that the risk for @entity5042 can be predicted based on the faecal microbial composition before colectomy. DESIGN: Faecal samples from 21 @entity1 with UC undergoing IPAA were prospectively collected before colectomy and at predefined clinical visits at 1 month, 3 months, 6 months and 12   months after IPAA. The predominant microbiota was analysed using community profiling with denaturing gradient gel electrophoresis followed by quantitative real-time PCR validation. RESULTS: Cluster analysis before colectomy distinguished @entity1 with @entity5042 from those with normal pouch during the 1st year of follow-up. In @entity1 developing @entity5042 , an increase of Ruminococcus gnavus (p<0.001), @entity3395 (p=0.043), @entity3168 (p=0.011) and a reduction of two Lachnospiraceae genera (Blautia (p=0.04), Roseburia (p=0.008)) was observed. A score combining these five bacterial risk factors was calculated and presence of at least two risk factors showed a sensitivity and specificity of 100% and 63.6%, respectively. CONCLUSIONS: Presence of R. gnavus, @entity3395 and @entity3168 and absence of Blautia and Roseburia in faecal samples of @entity1 with UC before surgery is associated with a higher risk of @entity5042 after IPAA. Our findings suggest new predictive and therapeutic strategies in @entity1 undergoing colectomy with IPAA.

title: Specific members of the predominant gut microbiota predict XXXX following colectomy and IPAA in UC.

entities_list: @entity5042 :: ('MESH:D019449', 'Disease') :: ['Pouchitis', 'pouchitis']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity3395 :: ('821', 'Species') :: ['B. vulgatus', 'Bacteroides vulgatus']

entities_list: @entity3168 :: ('1502', 'Species') :: ['C. perfringens', 'Clostridium perfringens']

answer: @entity5042 :: (MESH:D019449,Disease) :: ['pouchitis']


abstract: Genetic diversity within a species is a common feature, which plays a vital role in its survival and adaptability, and is important for the identification and authentication of a species. Lonicera japonica is a traditionally used medicinal plant, which have been recently genetically characterized by an improved ran- dom amplified polymorphic DNA (RAPD) analysis. In this study, the molecular markers on the basis of these RAPD fragments have been developed to identify specific @entity8470 variety. The DNAs were extracted from fresh young leaves of different samples of @entity8470 collected from Shenzhen, Yichang, Leshan, Emei and Loudi, China. The DNA materials were amplified using improved RAPD PCR. Different RAPD bands were excised, cloned and developed for stable @entity30 ( @entity30 ) markers with differ- ent species. Two @entity30 markers, JYH3-3 and JYH4-3, have been successfully cloned from improved.RAPD fragments. The @entity30 marker JYH3-3 was found specific for all of the @entity8470 samples collected from the different regions, and another marker JYH 4-3 was strictly specific to the Shenzhen sample from Guangdong province, which is geographically distant from Hubei, Sichuan and Hunan Provinces (source of other @entity8470 samples). The marker JYH3-3 was found as specific molecular marker for the identification of @entity8470 , while JYH4-3 was found as molecular marker strictly specific for the Shenzhen sample. The developed @entity30 markers might serve as more specific molecular markers for @entity8470 variety authentication. The combination of improved RAPD analysis and @entity30 marker development have resulted useful tools to study the genetic variety of any organism, which we have successfully applied here in @entity8470 .

title: Development of RAPD- XXXX markers for Lonicera japonica (Caprifolicaceae) variety authentication by improved RAPD and DNA cloning.

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['SCAR', 'sequence-characterized amplified region']

answer: @entity30 :: (MESH:D003424,Disease) :: ['SCAR']


abstract: PURPOSE: @entity1205 , @entity900 , and @entity1487 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity420 and is associated with significant @entity137 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity1 AND METHODS: Previously untreated @entity1 with metastatic gastric or GEJ @entity420 were randomly assigned to receive either mDCF ( @entity1487 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity1205 40 mg/m(2) IV on day 1, @entity900 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity1205 75 mg/m(2), @entity900 75 mg/m(2), and @entity1487 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity137 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity1 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity137 rates included 54% grade 3 to 4 @entity137 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity137 over the course of treatment. The DCF arm (n = 31) closed early because of @entity137 , with rates of 71% grade 3 to 4 @entity137 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity137 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity1 with metastatic gastric or GEJ @entity420 .

title: Randomized Multicenter Phase II Study of Modified @entity1205 , XXXX , and @entity1487 (DCF) Versus DCF Plus Growth Factor Support in @entity1 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']


abstract: PURPOSE: @entity1205 , @entity900 , and @entity1487 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity420 and is associated with significant @entity137 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity1 AND METHODS: Previously untreated @entity1 with metastatic gastric or GEJ @entity420 were randomly assigned to receive either mDCF ( @entity1487 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity1205 40 mg/m(2) IV on day 1, @entity900 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity1205 75 mg/m(2), @entity900 75 mg/m(2), and @entity1487 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity137 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity1 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity137 rates included 54% grade 3 to 4 @entity137 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity137 over the course of treatment. The DCF arm (n = 31) closed early because of @entity137 , with rates of 71% grade 3 to 4 @entity137 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity137 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity1 with metastatic gastric or GEJ @entity420 .

title: Randomized Multicenter Phase II Study of Modified @entity1205 , @entity900 , and @entity1487 (DCF) Versus DCF Plus Growth Factor Support in XXXX With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: PURPOSE: @entity1205 , @entity900 , and @entity1487 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity420 and is associated with significant @entity137 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity1 AND METHODS: Previously untreated @entity1 with metastatic gastric or GEJ @entity420 were randomly assigned to receive either mDCF ( @entity1487 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity1205 40 mg/m(2) IV on day 1, @entity900 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity1205 75 mg/m(2), @entity900 75 mg/m(2), and @entity1487 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity137 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity1 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity137 rates included 54% grade 3 to 4 @entity137 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity137 over the course of treatment. The DCF arm (n = 31) closed early because of @entity137 , with rates of 71% grade 3 to 4 @entity137 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity137 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity1 with metastatic gastric or GEJ @entity420 .

title: Randomized Multicenter Phase II Study of Modified @entity1205 , @entity900 , and XXXX (DCF) Versus DCF Plus Growth Factor Support in @entity1 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['Fluorouracil']


abstract: PURPOSE: @entity1205 , @entity900 , and @entity1487 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity420 and is associated with significant @entity137 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity1 AND METHODS: Previously untreated @entity1 with metastatic gastric or GEJ @entity420 were randomly assigned to receive either mDCF ( @entity1487 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity1205 40 mg/m(2) IV on day 1, @entity900 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity1205 75 mg/m(2), @entity900 75 mg/m(2), and @entity1487 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity137 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity1 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity137 rates included 54% grade 3 to 4 @entity137 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity137 over the course of treatment. The DCF arm (n = 31) closed early because of @entity137 , with rates of 71% grade 3 to 4 @entity137 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity137 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity1 with metastatic gastric or GEJ @entity420 .

title: Randomized Multicenter Phase II Study of Modified XXXX , @entity900 , and @entity1487 (DCF) Versus DCF Plus Growth Factor Support in @entity1 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['Docetaxel']


abstract: UNASSIGNED: In cavernous sinus (CS) surgery, venous complication may occur in some types of venous drainage. The sphenobasal vein (SBV) drains from the superficial middle cerebral vein (SMCV) to the pterygoid venous plexus at the temporal skull base. A frontotemporal epi- and interdural approach (Dolenc approach), which is one of the CS approaches, may damage the SBV's route. We report a case of intracavernous trigeminal schwannoma that contained the SBV and discuss our modified surgical procedure that combined epi- and subdural approaches to preserve the SBV. A 64-year-old @entity1 complained of right progressive @entity2895 and was referred to our hospital for surgery. MR images revealed a @entity548 in the right CS. Three-dimensional venography revealed that the SMCV drained into the pterygoid venous plexus via the SBV. After identifying the first branch of the trigeminal nerve epidurally, we incised the dura linearly along the sylvian fissure and entered the subdural space to visualize the SBV. The incision was continued to the meningeal dura of the lateral wall of the CS along the superior margin of the first branch of the trigeminal nerve, and the @entity191 was opened from the subdural side. The @entity5 was grossly totally removed, and the SBV was preserved. In conclusion, a frontotemporal epi- and subdural approach to the intracavernous trigeminal schwannoma can effectively preserve the SBV.

title: Frontotemporal epi- and subdural approach to a cavernous XXXX for sphenobasal vein preservation-technical case report.

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic tumor']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's triangle"]

entities_list: @entity2895 :: ('MESH:D015840', 'Disease') :: ['oculomotor palsy']

answer: @entity5 :: (MESH:D009369,Disease) :: ['sinus tumor']


abstract: Of 167 episodes of spinal epidural neoplastic compression, 86 were treated by operation. The surgical approach was prospectively selected according to the location of the @entity5 in the spinal canal. Decompression was achieved by 61 vertebral body resections (VBRs) and by 25 laminectomies. The indications for operation were: neurological relapse after previous radiotherapy, the need to make a tissue diagnosis, a @entity5 , and @entity16 during radiotherapy. Before VBR, 28% (17 of 61) were still able to walk, 51% (31 of 61) were parAparetic, and 21% (13 of 61) were paraplegic. Bowel and @entity1494 was present in 49% (30 of 61). After VBR, the outcome of only 57 procedures was available for evaluation because of the postoperative death of 4 @entity1 . Eighty per cent (46 of 57) were able to walk, 18% (10 of 57) were paraparetic, and 2% (1 of 57) were paraplegic. Ninety-three per cent had normal sphincter control. Before laminectomy, 8% (2 of 25) were ambulatory, 84% (21 of 25) were paraparetic, and 8% (2 of 25) were paraplegic. Bowel and @entity1494 was present in 76% (19 of 25). After laminectomy, only 23 procedures were evaluated because of the postoperative death of 2 @entity1 . Thirty-nine per cent (9 of 23) were ambulatory, 35% (8 of 23) were paraparetic, and 26% (6 of 23) were paraplegic. Fifty-seven per cent regained normal sphincter control. The operative mortality was 7% (4 of 61) in VBR and 8% (2 of 25) in laminectomy.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Surgical decompression of anterior and XXXX compressing the spinal cord: a prospective study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['radioresistant tumor', 'tumor']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological deterioration']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder dysfunction']

answer: @entity5 :: (MESH:D009369,Disease) :: ['posterior malignant epidural tumors']


abstract: BACKGROUND: @entity565 in the elderly (aged >=   65  years old) is a significant concern with high morbidity, but the pathophysiology remains unclear particularly in late-onset @entity565 . Recent studies suggest staphylococcal enterotoxin IgE (SE-IgE) sensitization to be a risk factor for @entity565 in general populations; however, the associations have not been examined in late-onset elderly @entity565 . OBJECTIVE: We aimed to examine the associations of @entity1793 with late-onset @entity565 in the elderly, using a database of elderly @entity565 cohort study. METHODS: A total of 249 elderly @entity1 with @entity565 and 98 controls were analysed. At baseline, @entity1 were assessed for demographics, atopy, induced sputum profiles and comorbidities including @entity102 ( @entity102 ). Serum total IgE and SE-IgE levels were measured. @entity565 severity was assessed on the basis of @entity565 outcomes during a 12-month follow-up period. RESULTS: At baseline, serum SE-IgE concentrations were significantly higher in @entity1 with @entity565 than in controls [median 0.16 (interquartile range 0.04-0.53) vs. 0.10 (0.01-0.19), P  <  0.001]. Elderly @entity565 @entity1 with high SE-IgE levels had specific characteristics of having more severe @entity565 , sputum @entity1712 and @entity102 , compared to those with lower SE-IgE levels. In multivariate logistic regression analyses, the associations between serum SE-IgE concentrations and severe @entity565 were significant, independently of covariables [SE-IgE-high (>=   0.35  kU/L) vs. negative (<  0.10  kU/L) group: odds ratio 7.47, 95% confidence interval 1.86-30.03, P  =  0.005]. Multiple correspondence analyses also showed that high serum SE-IgE level had close relationships with severe @entity565 , @entity102 and sputum @entity1712 together. CONCLUSIONS AND CLINICAL RELEVANCE: This is the first report on the significant associations of @entity1793 with late-onset @entity565 in the elderly, particularly severe @entity1712 with @entity102 comorbidity. Our findings indicate a potential implication of SE in the high morbidity burden of elderly @entity565 and suggest clues to the pathogenesis of severe late-onset @entity1712 in the elderly.

title: Staphylococcal enterotoxin IgE sensitization in late-onset severe XXXX in the elderly.

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia', 'eosinophilic asthma']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma', 'Asthma']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic rhinosinusitis', 'CRS']

entities_list: @entity1793 :: ('MESH:D013203', 'Disease') :: ['SE-IgE sensitization']

answer: @entity1712 :: (MESH:D004802,Disease) :: ['eosinophilic asthma']


abstract: UNASSIGNED: The Kidney Allocation System (KAS) aims to improve deceased donor kidney transplant outcomes by matching of donor allografts and kidney recipients using the kidney donor risk index (KDRI) and recipient estimated post-transplant survival (EPTS) indices. In this single-center study, KAS was retroactively applied to 573 adult deceased donor kidney transplants (2004-2012) performed in the extended criteria/standard criteria donor ( @entity13115 / @entity5099 ) era. Donor KDRI and recipient EPTS were calculated and transplants were analyzed to identify KAS fits. These were defined as allocation of top 20% allografts to top 20% recipients and bottom 80% allografts to bottom 80% recipients. On retroactive calculation, 70.2% of all transplants fit the KAS. Transplants that fit the KAS had inferior 1- and 5-year @entity1 survival (95.5% vs. 98.8%, p=0.048, and 83.4% vs. 91.7%, p=0.018) and similar 1- and 5-year graft survival compared to transplants that did not fit the KAS (91.3% vs. 94.1%, p=0.276, and 72.7% vs. 73.9%, p=0.561). While EPTS correlated with recipient survival (HR=2.96, p<0.001), KDRI correlated with both recipient (HR=3.56, p<0.001) and graft survival (HR=3.23, p<0.001). Overall, retroactive application of the KAS to transplants performed in the @entity13115 / @entity5099 era did not identify superior @entity1 survival for kidneys allocated in accordance with the KAS. This article is protected by copyright. All rights reserved.

title: Retroactive Application of the new Kidney Allocation System to Renal Transplants performed in the @entity13115 / XXXX era.

answer: @entity5099 :: (MESH:C536778,Disease) :: ['SCD']


abstract: UNASSIGNED: The Kidney Allocation System (KAS) aims to improve deceased donor kidney transplant outcomes by matching of donor allografts and kidney recipients using the kidney donor risk index (KDRI) and recipient estimated post-transplant survival (EPTS) indices. In this single-center study, KAS was retroactively applied to 573 adult deceased donor kidney transplants (2004-2012) performed in the extended criteria/standard criteria donor ( @entity13115 / @entity5099 ) era. Donor KDRI and recipient EPTS were calculated and transplants were analyzed to identify KAS fits. These were defined as allocation of top 20% allografts to top 20% recipients and bottom 80% allografts to bottom 80% recipients. On retroactive calculation, 70.2% of all transplants fit the KAS. Transplants that fit the KAS had inferior 1- and 5-year @entity1 survival (95.5% vs. 98.8%, p=0.048, and 83.4% vs. 91.7%, p=0.018) and similar 1- and 5-year graft survival compared to transplants that did not fit the KAS (91.3% vs. 94.1%, p=0.276, and 72.7% vs. 73.9%, p=0.561). While EPTS correlated with recipient survival (HR=2.96, p<0.001), KDRI correlated with both recipient (HR=3.56, p<0.001) and graft survival (HR=3.23, p<0.001). Overall, retroactive application of the KAS to transplants performed in the @entity13115 / @entity5099 era did not identify superior @entity1 survival for kidneys allocated in accordance with the KAS. This article is protected by copyright. All rights reserved.

title: Retroactive Application of the new Kidney Allocation System to Renal Transplants performed in the XXXX / @entity5099 era.

answer: @entity13115 :: (MESH:C567893,Disease) :: ['ECD']


abstract: UNASSIGNED: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is widely used in preoperative diagnosis of @entity5 . We investigated the clinical value of DCE-MRI in differential diagnosis of @entity2670 . The study involved 48 subjects with surgical pathology-confirmed @entity43 with solid components. Early dynamic phase enhancement performances of the @entity2670 in @entity1 were assessed, including the enhancement pattern, time-signal intensity curve (TIC), signal intensity rate at the initial 60  s (SI60), time to peak within 200  s (TTP200), and slope ratio. There were significant differences in enhancement patterns between benign and malignant @entity43 (P   <   0.05). A total of 30 @entity5 (30/31) displayed type I TIC, 8 @entity5 (8/13) showed type III TIC, and significant differences were found in TIC type between @entity2670 (P   <   0.01). @entity43 showed lower SI60 (%) and slope ratio, as well as significantly prolonged TTP20, compared to malignant @entity43 (all P   <   0.01). The microvessel count (MVC) of @entity5 was significantly higher than that of @entity5 (P   <   0.05). Receiver operating characteristic (ROC) curve analyses revealed that @entity9243 -MRI provided an optimal diagnostic performance with threshold values of SI60 at 83.40  %, TTP200 at 77.65  s, and slope ratio at 4.12. These findings revealed that @entity9243 -MRI provides critical information required for differential diagnosis of @entity2670 .

title: The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of XXXX .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian tumors', 'Benign ovarian tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['various tumors', 'malignant tumors', 'benign tumors']

entities_list: @entity2670 :: ('MESH:D010049', 'Disease') :: ['malignant and benign ovarian lesions', 'ovarian lesions']

answer: @entity2670 :: (MESH:D010049,Disease) :: ['malignant and benign ovarian lesions']


abstract: BACKGROUND: Survey data suggest that Canadian intensivists administer @entity288 to @entity3124 @entity1 primarily in response to @entity1224 , perceived risk for @entity1887 and @entity1344 . OBJECTIVE: To describe variables independently associated with systemic @entity228 therapy during an @entity683 outbreak. METHODS: The present analysis was retrospective cohort study involving @entity3124 @entity1 with @entity683 in two Canadian cities. Hospital records were reviewed for @entity3124 @entity1 treated in the intensive care units (ICUs) of eight hospitals in Canada during the 2008 to 2009 and 2009 to 2010 @entity683 outbreaks. Abstracted data included demographic information, symptoms at disease onset, chronic comorbidities and baseline illness severity scores. Corticosteroid use data were extracted for every ICU day and expressed as @entity701 dose equivalent in mg. Multivariable regression models were constructed to identify variables independently associated with corticosteroid therapy in the ICU. RESULTS: The study cohort included 90 @entity1 with a mean (   SD) age of 55.0  17.3 years and Acute Physiology and Chronic Health Evaluation II score of 19.8  8.3. @entity1 in 2009 to 2010 were younger with more severe @entity651 but similar exposure to @entity288 . Overall, 54% of @entity1 received @entity288 at a mean daily dose of 343  330 mg of @entity701 for 8.5  4.8 days. Variables independently associated with corticosteroid therapy in the ICU were history of @entity1224 (OR 4.8 [95% CI 1.6 to 14.9]) and @entity1344 (OR 4.6 [95% CI 1.2 to 17.8]). CONCLUSION: Observational data revealed that @entity1344 and @entity1224 were associated with corticosteroid therapy in the critical care setting, similar to a recent survey of stated practice. Efforts to determine the effects of @entity288 in the ICU for these specific clinical situations are warranted.

title: @entity228 therapy in XXXX due to seasonal and pandemic @entity683 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critically ill']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['hydrocortisone']

entities_list: @entity1344 :: ('MESH:D043171', 'Disease') :: ['hemodynamic instability']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway obstruction']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity3124 :: (MESH:D016638,Disease) :: ['critical illness']


abstract: BACKGROUND: Survey data suggest that Canadian intensivists administer @entity288 to @entity3124 @entity1 primarily in response to @entity1224 , perceived risk for @entity1887 and @entity1344 . OBJECTIVE: To describe variables independently associated with systemic @entity228 therapy during an @entity683 outbreak. METHODS: The present analysis was retrospective cohort study involving @entity3124 @entity1 with @entity683 in two Canadian cities. Hospital records were reviewed for @entity3124 @entity1 treated in the intensive care units (ICUs) of eight hospitals in Canada during the 2008 to 2009 and 2009 to 2010 @entity683 outbreaks. Abstracted data included demographic information, symptoms at disease onset, chronic comorbidities and baseline illness severity scores. Corticosteroid use data were extracted for every ICU day and expressed as @entity701 dose equivalent in mg. Multivariable regression models were constructed to identify variables independently associated with corticosteroid therapy in the ICU. RESULTS: The study cohort included 90 @entity1 with a mean (   SD) age of 55.0  17.3 years and Acute Physiology and Chronic Health Evaluation II score of 19.8  8.3. @entity1 in 2009 to 2010 were younger with more severe @entity651 but similar exposure to @entity288 . Overall, 54% of @entity1 received @entity288 at a mean daily dose of 343  330 mg of @entity701 for 8.5  4.8 days. Variables independently associated with corticosteroid therapy in the ICU were history of @entity1224 (OR 4.8 [95% CI 1.6 to 14.9]) and @entity1344 (OR 4.6 [95% CI 1.2 to 17.8]). CONCLUSION: Observational data revealed that @entity1344 and @entity1224 were associated with corticosteroid therapy in the critical care setting, similar to a recent survey of stated practice. Efforts to determine the effects of @entity288 in the ICU for these specific clinical situations are warranted.

title: XXXX therapy in @entity3124 due to seasonal and pandemic @entity683 .

answer: @entity228 :: (CHEBI:50858,Chemical) :: ['Corticosteroid']


abstract: BACKGROUND: Survey data suggest that Canadian intensivists administer @entity288 to @entity3124 @entity1 primarily in response to @entity1224 , perceived risk for @entity1887 and @entity1344 . OBJECTIVE: To describe variables independently associated with systemic @entity228 therapy during an @entity683 outbreak. METHODS: The present analysis was retrospective cohort study involving @entity3124 @entity1 with @entity683 in two Canadian cities. Hospital records were reviewed for @entity3124 @entity1 treated in the intensive care units (ICUs) of eight hospitals in Canada during the 2008 to 2009 and 2009 to 2010 @entity683 outbreaks. Abstracted data included demographic information, symptoms at disease onset, chronic comorbidities and baseline illness severity scores. Corticosteroid use data were extracted for every ICU day and expressed as @entity701 dose equivalent in mg. Multivariable regression models were constructed to identify variables independently associated with corticosteroid therapy in the ICU. RESULTS: The study cohort included 90 @entity1 with a mean (   SD) age of 55.0  17.3 years and Acute Physiology and Chronic Health Evaluation II score of 19.8  8.3. @entity1 in 2009 to 2010 were younger with more severe @entity651 but similar exposure to @entity288 . Overall, 54% of @entity1 received @entity288 at a mean daily dose of 343  330 mg of @entity701 for 8.5  4.8 days. Variables independently associated with corticosteroid therapy in the ICU were history of @entity1224 (OR 4.8 [95% CI 1.6 to 14.9]) and @entity1344 (OR 4.6 [95% CI 1.2 to 17.8]). CONCLUSION: Observational data revealed that @entity1344 and @entity1224 were associated with corticosteroid therapy in the critical care setting, similar to a recent survey of stated practice. Efforts to determine the effects of @entity288 in the ICU for these specific clinical situations are warranted.

title: @entity228 therapy in @entity3124 due to seasonal and pandemic XXXX .

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza']


abstract: Achievements in radiotherapy of @entity135 continue. During the past decade, bench marks have been established for certain early staged @entity5 . Technical advances have occurred in higher energy accelerators with the development of dual photon and medium-range electron machines. Imaging technology has augmented precision @entity5 localization and staging, and its marriage to computerized treatment planning is leading the way toward an optimization of delivered radiation dose to the @entity5 volume. Neutron therapy is finding a definite place in moderately advanced @entity135 , and its wider use awaits further developments in compact neutron generators. @entity221 combined with photon radiation is undergoing serious clinical trials, and this combination appears to be most promising. The search for radiation sensitizers to enhance @entity5 destruction and for radioprotectors for normal tissue continues. Progress in the latter appears encouraging. Burgeoning radiobiologic data have led the way to several dose fractionation schemes, and the most promising clinically appears to be hyperfractionation. Combinations of surgery and radiotherapy have improved cure rates in moderately advanced @entity5 , but a preference between preoperative and postoperative radiotherapy in specific sites is still controversial. The medical oncologist has become a valued member of the interdisciplinary team rather than remaining solely the recipient of failed radiotherapeutic and surgical @entity1 . There is a keener awareness of the difficulties and intricacies involved in the construction and evaluation of clinical trials and results.

title: Radiotherapy for XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'head and neck cancers']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['Hyperthermia']

answer: @entity135 :: (MESH:D006258,Disease) :: ['cancer of the head and neck']


abstract: UNASSIGNED: The environment within the spinal cord after injury, which changes in the progression from the acute to chronic stages, limits the extent of regeneration. The delivery of inductive factors to promote regeneration following spinal @entity1566 has been promising, yet, few strategies are versatile to allow delivery during acute or chronic injury that would facilitate screening of candidate therapies. This report investigates the intrathecal delivery of lentiviruses for long-term expression of regenerative factors. Lentivirus-filled sponges were inserted into the intrathecal space surrounding the spinal cord, with transgene expression observed within multiple cell types that persists for 12weeks for both intact and injured spinal cord, without any apparent damage to the spinal cord tissue. Sponges loaded with lentivirus encoding for @entity4851 ( @entity4851 ) were investigated for acute (delivered at 0weeks) and chronic (at 4weeks) injuries, and for multiple locations relative to the injury. In an acute model, sponges placed directly above the injury increased oligodendrocyte and decreased astrocyte presence. Sponges placed caudal to the injury had reduced impact on oligodendrocytes and astrocytes in the injury. In a chronic model, sponges increased oligodendrocyte and decreased astrocyte presence. Furthermore, the effect of @entity4851 was shown to be mediated in part by reduction of @entity6861 signaling, monitored with an @entity21506 -sensitive reporter vector. The implantation of lentivirus-loaded biomaterials intrathecally provides the opportunity to induce the expression of a factor at a specified time without entering the spinal cord, and has the potential to promote gene delivery within the spinal cord, which can influence the extent of regeneration.

title: Sponge-mediated lentivirus delivery to acute and chronic XXXX .

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['cord injury']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injuries']


abstract: BACKGROUND AND OBJECTIVE: Amitriptyline, a frequently used tricyclic antidepressant agent, has powerful @entity1370 effects especially in high doses. Serum and urine levels of amitriptyline dosages are not correlated with severity of @entity137 ; therefore, it increases the importance of electrocardiography (ECG) abnormalities. The prolongation of QTc can be a predictive marker for @entity1370 . Hence, in this study, it is aimed to evaluate possible effects of metoprolol and diltiazem in amitriptyline @entity137 . MATERIALS AND METHODS: The @entity35 were separated into four groups. First one was control group, the second was the amitriptyline + saline group, third one was the amitriptyline + metoprolol group, and forth one was the amitriptyline + diltiazem group. ECG were recorded on @entity35 under anesthesia. RESULTS: In amitriptyline group, QTc duration was prolonged compared with all other groups. The prolongation of QTc was shorter in amitriptyline + metoprolol group and amitriptyline + diltiazem group than amitriptyline group (p < 0.01 and p < 0.01, respectively). CONCLUSION: According to the results, it is possible to report ameliorating effects of both metoprolol and diltiazem on @entity1162 related with amitriptyline intoxication. With further studies, these agents may be used for amitriptyline @entity137 and besides, they may be used for @entity1 in cardiovascular risk groups who take amitriptyline treatment regularly.

title: The effects of diltiazem and metoprolol in XXXX due to amitriptyline intoxication.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['QTc prolongation']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxic', 'cardiotoxicity']

answer: @entity1162 :: (MESH:D008133,Disease) :: ['QTc prolongation']


abstract: PURPOSES: The purpose of this study was to retrospectively study @entity5 with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR ( @entity5 with abundant @entity8125 ), @entity6196 , and @entity6196 , in order to improve their descriptions and try to better define therapeutic modalities. METHODS: @entity1 with ETMR, ETAN-TR, @entity6196 , and @entity6196 treated in SFCE centres (Soci  t   Fran  aise de lutte contre les Cancers et les leuc  mies de l'Enfant et de l'adolescent) since 2000 were collected. Data were retrieved from clinical charts. RESULTS: Thirty-eight @entity1 were included in the analysis. Seventeen had an ETAN-TR, 13 had a @entity6196 , and 8 had an ETMR. No @entity6196 was included. The median age at diagnosis was 31  months (range, 2.8-141  months). The predominant @entity5 location was supratentorial (66  %); 18.4  % @entity1 had metastatic lesion. @entity26534 expression was positive in 11/11 @entity1 . Amplification of the locus 19q13.42 was positive in 10/12 @entity1 . Thirty @entity1 were treated according to the primitive @entity4969 of high risk (PNET-HR) protocol. The median time of follow-up was 0.9  years (range 0.1 to 15.3  years). The 1-year event-free survival (EFS) and overall survival (OS) were, respectively, 36  % CI 95  % (23-55) and 45  % CI 95  % (31-64). On multivariate analysis, complete surgical resection, radiotherapy, and high-dose chemotherapy were associated with a better overall survival with a relative risk of, respectively, 7.9 CI 95  % (2.6-23.5) p  <  0.0002, 41.8 CI 95  % (9.4-186) p  <  0.0001, and 3.5 CI 95  % (1.3-9.5) p  =  0.012. CONCLUSION: Prognosis of ETMR remains dismal despite multimodal therapy. @entity26534 immunostaining and 19q13.42 amplification should be systematically done to secure the diagnosis. Complete surgical resection, radiotherapy, and high-dose chemotherapy are associated with better outcome.

title: XXXX with multilayered rosettes in @entity1 : the SFCE experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6196 :: ('MESH:D018242', 'Disease') :: ['medulloepithelioma', 'ependymoblastoma', 'medulloepitheliomas', 'ependymoblastomas']

entities_list: @entity4969 :: ('MESH:D017599', 'Disease') :: ['neuroectodermal tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'embryonal tumors', 'embryonal tumor']

entities_list: @entity8125 :: ('MESH:C579935', 'Disease') :: ['neuropil and true rosettes']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Embryonal tumors']


abstract: PURPOSES: The purpose of this study was to retrospectively study @entity5 with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR ( @entity5 with abundant @entity8125 ), @entity6196 , and @entity6196 , in order to improve their descriptions and try to better define therapeutic modalities. METHODS: @entity1 with ETMR, ETAN-TR, @entity6196 , and @entity6196 treated in SFCE centres (Soci  t   Fran  aise de lutte contre les Cancers et les leuc  mies de l'Enfant et de l'adolescent) since 2000 were collected. Data were retrieved from clinical charts. RESULTS: Thirty-eight @entity1 were included in the analysis. Seventeen had an ETAN-TR, 13 had a @entity6196 , and 8 had an ETMR. No @entity6196 was included. The median age at diagnosis was 31  months (range, 2.8-141  months). The predominant @entity5 location was supratentorial (66  %); 18.4  % @entity1 had metastatic lesion. @entity26534 expression was positive in 11/11 @entity1 . Amplification of the locus 19q13.42 was positive in 10/12 @entity1 . Thirty @entity1 were treated according to the primitive @entity4969 of high risk (PNET-HR) protocol. The median time of follow-up was 0.9  years (range 0.1 to 15.3  years). The 1-year event-free survival (EFS) and overall survival (OS) were, respectively, 36  % CI 95  % (23-55) and 45  % CI 95  % (31-64). On multivariate analysis, complete surgical resection, radiotherapy, and high-dose chemotherapy were associated with a better overall survival with a relative risk of, respectively, 7.9 CI 95  % (2.6-23.5) p  <  0.0002, 41.8 CI 95  % (9.4-186) p  <  0.0001, and 3.5 CI 95  % (1.3-9.5) p  =  0.012. CONCLUSION: Prognosis of ETMR remains dismal despite multimodal therapy. @entity26534 immunostaining and 19q13.42 amplification should be systematically done to secure the diagnosis. Complete surgical resection, radiotherapy, and high-dose chemotherapy are associated with better outcome.

title: @entity5 with multilayered rosettes in XXXX : the SFCE experience.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: PURPOSE: To report the association of a mosaic enhancement pattern on contrast-enhanced CT or MR imaging and @entity99 ( @entity384 ) with acute inflammatory conditions affecting extrahepatic organs. METHODS: From 2007 to 2012, @entity1 with acute inflammatory diseases who underwent contrast-enhanced CT and/or MRI of the liver with a mosaic enhancement pattern were selected. Clinico-biological and other imaging features were collected at diagnosis and during follow-up. RESULTS: Sixteen @entity1 were included (15 @entity1 , median age 27  years; range 18-68). Five @entity1 (33  %) were receiving @entity7280 . Acute inflammatory diseases included @entity2885 (n   =   10), @entity788 (n   =   2), @entity55 (n   =   1), @entity295 (n   =   1), active @entity30 (n   =   1), and @entity1960 (n   =   1). Median white blood cell count was 13,250 cells/ L (range 11,500-18,000 cells/ L) and CRP level 94  mg/L (range 60-121  mg/L). Mosaic enhancement pattern was present in the whole liver and was prominent in the subcapsular areas. Four @entity1 underwent liver biopsy confirming @entity384 . Eleven @entity1 underwent follow-up imaging showing normalized aspect in 9/11 @entity1 after a median of 2  months. CONCLUSION: @entity697 of extrahepatic organs, associated with a marked systemic inflammatory syndrome should be added to the list of conditions causing a reversible @entity99 as manifested by a mosaic enhancement pattern on contrast-enhanced CT or MR imaging. KEY POINTS:     Acute @entity6687 /inflammatory diseases are a cause of transient @entity2468 .     In most @entity1 , @entity2468 was seen during both arterial and portal venous phase.     In all @entity1 , the mosaic enhancement pattern was diffuse, but more conspicuous in subcapsular areas.     @entity2468 was no longer seen after resolution of the @entity697 .     No liver biopsy should be performed.

title: Acute XXXX or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to @entity384 of the liver.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute diseases', 'acute disease']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity1960 :: ('MESH:D003092', 'Disease') :: ['infectious colitis']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['pyelonephritis']

entities_list: @entity6687 :: ('MESH:D001651', 'Disease') :: ['extrahepatic infectious']

entities_list: @entity7280 :: ('MESH:D003276', 'Chemical') :: ['oral contraceptives']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic sinusoidal dilatation']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity6687 :: (MESH:D001651,Disease) :: ['extrahepatic infectious']


abstract: PURPOSE: To report the association of a mosaic enhancement pattern on contrast-enhanced CT or MR imaging and @entity99 ( @entity384 ) with acute inflammatory conditions affecting extrahepatic organs. METHODS: From 2007 to 2012, @entity1 with acute inflammatory diseases who underwent contrast-enhanced CT and/or MRI of the liver with a mosaic enhancement pattern were selected. Clinico-biological and other imaging features were collected at diagnosis and during follow-up. RESULTS: Sixteen @entity1 were included (15 @entity1 , median age 27  years; range 18-68). Five @entity1 (33  %) were receiving @entity7280 . Acute inflammatory diseases included @entity2885 (n   =   10), @entity788 (n   =   2), @entity55 (n   =   1), @entity295 (n   =   1), active @entity30 (n   =   1), and @entity1960 (n   =   1). Median white blood cell count was 13,250 cells/ L (range 11,500-18,000 cells/ L) and CRP level 94  mg/L (range 60-121  mg/L). Mosaic enhancement pattern was present in the whole liver and was prominent in the subcapsular areas. Four @entity1 underwent liver biopsy confirming @entity384 . Eleven @entity1 underwent follow-up imaging showing normalized aspect in 9/11 @entity1 after a median of 2  months. CONCLUSION: @entity697 of extrahepatic organs, associated with a marked systemic inflammatory syndrome should be added to the list of conditions causing a reversible @entity99 as manifested by a mosaic enhancement pattern on contrast-enhanced CT or MR imaging. KEY POINTS:     Acute @entity6687 /inflammatory diseases are a cause of transient @entity2468 .     In most @entity1 , @entity2468 was seen during both arterial and portal venous phase.     In all @entity1 , the mosaic enhancement pattern was diffuse, but more conspicuous in subcapsular areas.     @entity2468 was no longer seen after resolution of the @entity697 .     No liver biopsy should be performed.

title: Acute @entity6687 or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to XXXX of the liver.

answer: @entity384 :: (MESH:D002311,Disease) :: ['sinusoidal dilatation']


abstract: OBJECTIVE: To review childhood @entity1 with @entity5683 ( @entity5683 ) who underwent surgery at Hospital Infantil Ni  o Jes  s of Madrid since January 1981 to September 2014. MATERIAL AND METHODS: Registered charts were analyzed based on the epidemiology, @entity5 grade, clinical profile, location, dissemination characteristics, therapy, prognosis and complications. RESULTS: Seventeen childhood @entity1 were recorded with @entity5683 . Cases were distributed so that 9 cases were @entity2846 ( @entity2846 ) (52.9%), 2 cases atypical @entity2846 (11.7%) and 6 cases @entity9204 ( @entity9204 ) (35.2%). Age at diagnosis was less than 2 years in 14 of the 17 @entity1 (82.3%) and the incidence was higher in males (82.3% of the cases). Gross total resection was performed in 16 @entity1 (94.1%). Adjuvant treatment was used in 6 @entity1 (all this cases with @entity9204 ) (35.2%). Two of the 17 @entity1 died (11.7%), showing an incidence density of 0.01 @entity204 /year. CONCLUSIONS: Our case series is consistent with previous published in scientific literature regarding epidemiology, @entity5 grade, clinical presentation, radiological features and therapeutic approach. Gross total resection is considered the therapeutic gold standard for @entity5683 . Chemotherapy and radiotherapy should be used as adjuvant treatment in @entity9204 and recurrent or remaining atypical @entity2846 .

title: [ XXXX treatment at Hospital Infantil Ni  o Jes  s in Madrid: Our experience over the last three decades.]

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5683 :: ('MESH:D016545', 'Disease') :: ['choroid plexus tumors', 'CPT']

entities_list: @entity2846 :: ('MESH:D020288', 'Disease') :: ['CPP', 'choroid plexus-papilloma']

entities_list: @entity9204 :: ('MESH:C562943', 'Disease') :: ['CPC', 'choroid plexus-carcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Choroid plexus tumour']


abstract: UNASSIGNED: The aim of the study was to find whether @entity1 carrying polymorphic allele of the @entity29766 polymorphism from 9p21 locus have changed risk of @entity943 ( @entity955 , AF; sustained @entity1165 or @entity2224 , sVT/VF) during acute phase of @entity583 . Retrospective analysis of data collected prospectively from two independent centers was performed. The clinical data were pooled from two independent cardiac registries: (1) the Warsaw ACS genetic registry (STEMI and NSTEMI/UA @entity1 hospitalized in the years 2008-2011; only STEMI @entity1 were analyzed); (2) the Bialystok STEMI genetic registry (STEMI @entity1 hospitalized in years 2001-2005, who survived the first 48  h from hospital admission). Data regarding sVT/VF and AF within first 24  h were analyzed. The @entity1 were genotyped with @entity29766 polymorphism. 1083 @entity1 were included in the analysis; 62 (5.7  %) @entity1 had sVT/VF during acute phase and 78 (7.2  %) @entity1 had AF, 46 (4.2  %) @entity1 had new-onset AF. Minor allele frequency in all @entity1 with AF was significantly different from those without AF (0.40 vs 0.51, p  =  0.0096). When only new-onset AF was analyzed, the trend was the same, with significant protective effect in recessive model [OR 0.41 (95  % CI 0.17-0.97), p  =  0.025]. The effect was independent of age and GRACE score. No relationship was found between sVT/VF and @entity29766 . @entity1 with STEMI, who survived until hospitalization with polymorphic allele of 9p21 @entity29766 SNP have less AF during acute phase of STEMI. SNP @entity29766 is not linked with sVT/VF in acute phase of STEMI.

title: The 9p21 polymorphism is linked with XXXX during acute phase of ST-segment elevation @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: UNASSIGNED: The aim of the study was to find whether @entity1 carrying polymorphic allele of the @entity29766 polymorphism from 9p21 locus have changed risk of @entity943 ( @entity955 , AF; sustained @entity1165 or @entity2224 , sVT/VF) during acute phase of @entity583 . Retrospective analysis of data collected prospectively from two independent centers was performed. The clinical data were pooled from two independent cardiac registries: (1) the Warsaw ACS genetic registry (STEMI and NSTEMI/UA @entity1 hospitalized in the years 2008-2011; only STEMI @entity1 were analyzed); (2) the Bialystok STEMI genetic registry (STEMI @entity1 hospitalized in years 2001-2005, who survived the first 48  h from hospital admission). Data regarding sVT/VF and AF within first 24  h were analyzed. The @entity1 were genotyped with @entity29766 polymorphism. 1083 @entity1 were included in the analysis; 62 (5.7  %) @entity1 had sVT/VF during acute phase and 78 (7.2  %) @entity1 had AF, 46 (4.2  %) @entity1 had new-onset AF. Minor allele frequency in all @entity1 with AF was significantly different from those without AF (0.40 vs 0.51, p  =  0.0096). When only new-onset AF was analyzed, the trend was the same, with significant protective effect in recessive model [OR 0.41 (95  % CI 0.17-0.97), p  =  0.025]. The effect was independent of age and GRACE score. No relationship was found between sVT/VF and @entity29766 . @entity1 with STEMI, who survived until hospitalization with polymorphic allele of 9p21 @entity29766 SNP have less AF during acute phase of STEMI. SNP @entity29766 is not linked with sVT/VF in acute phase of STEMI.

title: The 9p21 polymorphism is linked with @entity955 during acute phase of ST-segment elevation XXXX .

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: BACKGROUND _ AIMS: Fecal immunochemical tests (FITs) are used widely in @entity14 screening. Programs use the same fecal hemoglobin threshold for colonoscopy referral for @entity1 and @entity1 , but it is unclear whether FIT performs equally in both sexes. We therefore assessed FIT performance in @entity1 and @entity1 . METHODS: A prospective cohort study was performed, in which a total of 10,008 average-risk subjects (age, 50-74 y) were invited for first-round screening and 8316 average-risk subjects (age, 51-74 y) were invited for second-round screening with a single FIT. Subjects with a hemoglobin (Hb) level of 10  g hemoglobin (Hb)/g (or >= 50 ng/mL) feces or higher were referred for colonoscopy. The test characteristics were assessed by sex for a range of FIT cut-off values. RESULTS: In total, 59.8% of @entity1 and 64.6% of @entity1 participated in the first round (P < .001). At a cut-off level of 10  g Hb/g, the positivity rate was significantly higher among @entity1 (10.7%) compared with @entity1 (6.3%; P < .001) in the first round. The detection rate of advanced @entity5 was 4.4% for @entity1 and 2.2% for @entity1 (P < .001) in the first round. The positive predictive value for advanced @entity5 in the first round was 42% for @entity1 and 37% for @entity1 (P  = .265). A significantly higher false-positive rate in @entity1 (6.3%) than in @entity1 (4.1%; P < .001) was found. Similar differences in these test characteristics were seen in the second round. CONCLUSIONS: At a cut-off level of 10  g Hb/g the FIT positivity rate was higher in @entity1 , reflected by both a higher detection rate and a higher false-positive rate. The use of the same cut-off value in @entity1 and @entity1 in FIT screening is recommended based on equal test performance in terms of positive predictive value.

title: Gender Differences in Fecal Immunochemical Test Performance for Early Detection of XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasia']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['Colorectal Neoplasia']


abstract: UNASSIGNED: Previous descriptions of the clinical features of @entity66 occurred before the widespread use of magnetic resonance imaging (MRI) allowed a more definitive diagnosis of @entity158 . The objective of this study was to compare the clinical features of @entity1641 with lesions of the podotrochlear apparatus with those with other causes of @entity158 . It was hypothesised that @entity79 would be associated with more advanced radiological findings than other diagnoses. A retrospective study was performed of all @entity1641 examined at a referral centre with a definitive diagnosis of @entity158 based on MRI        post-mortem examination. Clinical examination findings, response to diagnostic analgesia and radiological grading of the navicular bone were compared among five diagnosis groups: (1) primary @entity79 ( @entity79 ); (2) lesions of the collateral sesamoidean ligament and/or distal sesamoidean impar ligament (CSL   +   DSIL); (3) primary @entity1796 ( @entity1796 ); (4) @entity79 and other lesions of the podotrochlear apparatus        @entity1796 (PTA) and (5) Other. There were 702 @entity1641 ( @entity79 , 62; CSL   +   DSIL, 180; @entity1796 , 69; PTA, 92; Other, 299). @entity1641 with PTA injuries were more frequently unilaterally lame than other groups (P   =   0.04). @entity1641 with @entity130 were more likely to exhibit @entity158 on turning than other groups (P   <0.01). There were no associations between response to diagnostic analgesia and diagnostic group, and no association between radiological grade and diagnostic group. Clinical examination findings generally did not discriminate between diseases of the PTA and other causes of @entity158 . Overall radiological scores of the navicular bone did not accurately predict @entity79 .

title: Is there an association between clinical features, response to diagnostic analgesia and radiological findings in @entity1641 with a magnetic resonance imaging diagnosis of XXXX or other injuries of the podotrochlear apparatus?

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['navicular disease']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['NB', 'primary navicular bone disease', 'navicular bone pathology']

entities_list: @entity1796 :: ('MESH:D013708', 'Disease') :: ['DDFT', 'deep digital flexor tendon injury']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['foot pain', 'pain']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['DDFT injury']

answer: @entity66 :: (MESH:D004194,Disease) :: ['navicular disease']


abstract: UNASSIGNED: Previous descriptions of the clinical features of @entity66 occurred before the widespread use of magnetic resonance imaging (MRI) allowed a more definitive diagnosis of @entity158 . The objective of this study was to compare the clinical features of @entity1641 with lesions of the podotrochlear apparatus with those with other causes of @entity158 . It was hypothesised that @entity79 would be associated with more advanced radiological findings than other diagnoses. A retrospective study was performed of all @entity1641 examined at a referral centre with a definitive diagnosis of @entity158 based on MRI        post-mortem examination. Clinical examination findings, response to diagnostic analgesia and radiological grading of the navicular bone were compared among five diagnosis groups: (1) primary @entity79 ( @entity79 ); (2) lesions of the collateral sesamoidean ligament and/or distal sesamoidean impar ligament (CSL   +   DSIL); (3) primary @entity1796 ( @entity1796 ); (4) @entity79 and other lesions of the podotrochlear apparatus        @entity1796 (PTA) and (5) Other. There were 702 @entity1641 ( @entity79 , 62; CSL   +   DSIL, 180; @entity1796 , 69; PTA, 92; Other, 299). @entity1641 with PTA injuries were more frequently unilaterally lame than other groups (P   =   0.04). @entity1641 with @entity130 were more likely to exhibit @entity158 on turning than other groups (P   <0.01). There were no associations between response to diagnostic analgesia and diagnostic group, and no association between radiological grade and diagnostic group. Clinical examination findings generally did not discriminate between diseases of the PTA and other causes of @entity158 . Overall radiological scores of the navicular bone did not accurately predict @entity79 .

title: Is there an association between clinical features, response to diagnostic analgesia and radiological findings in XXXX with a magnetic resonance imaging diagnosis of @entity66 or other injuries of the podotrochlear apparatus?

answer: @entity1641 :: (9796,Species) :: ['horses']


abstract: OBJECTIVES: Management of @entity1 with @entity697 ( @entity697 ) and @entity1779 secondary to occlusion or @entity850 of the left common carotid artery (LCCA) or right common carotid artery (RCCA) is a significant challenge. The aim of this study is to present our institutional strategy and postoperative results for this high-risk @entity1 cohort. METHODS: Between November 2005 and July 2013, 23 of 354 consecutively operated @entity697 @entity1 [median age: 66.3; interquartile range (IQR): 55.2-69.9] suffered from @entity1779 due to bilateral (n = 1) or unilateral occlusion of the LCCA/RCCA (n = 22). @entity697 repair comprised hemi- (n = 14) or total (n = 9) arch replacement in combination with aortic valve repair (n = 7) or replacement (n = 11), root replacement (n = 15) and coronary bypass (n = 3). Extra-anatomic aorto-carotid bypass was performed in all @entity1 . Aorto-carotid bypass was performed at the beginning of the procedure to allow for unilateral selective cerebral perfusion (n = 17; 73.9%) or during the procedure if persisting malperfusion was suspected by near-infrared spectroscopy (n = 6; 26.1%). RESULTS: The median follow-up was 15.2 months (IQR: 4.8-34.1) and 100% complete. Median hospital stay and ICU stay were 16.0 (IQR: 12.5-26.0) and 13.7 (IQR: 2.0-16.5) days, respectively. Rethoracotomy for @entity548 or @entity2293 was performed in 6 (26.1%) @entity1 . Other @entity260 comprised low cardiac output with extracorporeal membrane oxygenation (n = 2; 8.7%), @entity295 (n = 4; 17.4%), @entity1576 (n = 10; 43.5%), @entity177 with temporary dialysis (n = 7; 30.4%) and visceral malperfusion (n = 2; 8.7%) requiring stent grafting (n = 1) or laparotomy with intestinal resection (n = 1). @entity64 with or without permanent @entity3481 was diagnosed in 8 (34.8%) @entity1 . @entity51 were seen in 9 (39.1%) individuals. Hospital and 1-year mortality rates were 13.0 and 30.4%, respectively. Overall survival after 36 months of the 23 @entity1 (Group I = Extra-anatomic bypass) versus the remaining 331 @entity697 @entity1 without @entity432 (Group II = no extra-anatomic bypass) was 69.6% (n = 16) in Group I vs 72.5% (n = 240) in Group II (P = 0.90). CONCLUSION: Extra-anatomic bypass for LCCA or @entity432 allows for early selective cerebral perfusion during @entity697 repair, and may reduce the risk of @entity16 in @entity1 with preoperative @entity1779 .

title: Extra-anatomic revascularization for preoperative @entity1779 due to distal carotid artery occlusion in XXXX   .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['AADA', 'acute aortic dissection type A']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['New stroke']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage']

entities_list: @entity2293 :: ('MESH:D002305', 'Disease') :: ['cardiac tamponade']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity3481 :: ('MESH:D015417', 'Disease') :: ['sensory or motor deficit']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['Temporary neurological deficits']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory insufficiency']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['distal RCCA/LCCA occlusion', 'RCCA occlusion']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['cerebral malperfusion']

answer: @entity697 :: (MESH:D000208,Disease) :: ['acute type A aortic dissection']


abstract: OBJECTIVES: Management of @entity1 with @entity697 ( @entity697 ) and @entity1779 secondary to occlusion or @entity850 of the left common carotid artery (LCCA) or right common carotid artery (RCCA) is a significant challenge. The aim of this study is to present our institutional strategy and postoperative results for this high-risk @entity1 cohort. METHODS: Between November 2005 and July 2013, 23 of 354 consecutively operated @entity697 @entity1 [median age: 66.3; interquartile range (IQR): 55.2-69.9] suffered from @entity1779 due to bilateral (n = 1) or unilateral occlusion of the LCCA/RCCA (n = 22). @entity697 repair comprised hemi- (n = 14) or total (n = 9) arch replacement in combination with aortic valve repair (n = 7) or replacement (n = 11), root replacement (n = 15) and coronary bypass (n = 3). Extra-anatomic aorto-carotid bypass was performed in all @entity1 . Aorto-carotid bypass was performed at the beginning of the procedure to allow for unilateral selective cerebral perfusion (n = 17; 73.9%) or during the procedure if persisting malperfusion was suspected by near-infrared spectroscopy (n = 6; 26.1%). RESULTS: The median follow-up was 15.2 months (IQR: 4.8-34.1) and 100% complete. Median hospital stay and ICU stay were 16.0 (IQR: 12.5-26.0) and 13.7 (IQR: 2.0-16.5) days, respectively. Rethoracotomy for @entity548 or @entity2293 was performed in 6 (26.1%) @entity1 . Other @entity260 comprised low cardiac output with extracorporeal membrane oxygenation (n = 2; 8.7%), @entity295 (n = 4; 17.4%), @entity1576 (n = 10; 43.5%), @entity177 with temporary dialysis (n = 7; 30.4%) and visceral malperfusion (n = 2; 8.7%) requiring stent grafting (n = 1) or laparotomy with intestinal resection (n = 1). @entity64 with or without permanent @entity3481 was diagnosed in 8 (34.8%) @entity1 . @entity51 were seen in 9 (39.1%) individuals. Hospital and 1-year mortality rates were 13.0 and 30.4%, respectively. Overall survival after 36 months of the 23 @entity1 (Group I = Extra-anatomic bypass) versus the remaining 331 @entity697 @entity1 without @entity432 (Group II = no extra-anatomic bypass) was 69.6% (n = 16) in Group I vs 72.5% (n = 240) in Group II (P = 0.90). CONCLUSION: Extra-anatomic bypass for LCCA or @entity432 allows for early selective cerebral perfusion during @entity697 repair, and may reduce the risk of @entity16 in @entity1 with preoperative @entity1779 .

title: Extra-anatomic revascularization for preoperative XXXX due to distal carotid artery occlusion in @entity697   .

answer: @entity1779 :: (MESH:D002543,Disease) :: ['cerebral malperfusion']


abstract: BACKGROUND AND AIMS: The introduction of Duke's criteria and the improvement of imaging methods has lead to an earlier and a more accurate diagnosis of @entity166 ( @entity166 ). The options for the best therapeutic approach and the timing of surgery are still a matter of debate and require a close colaboration between the cardiologist, the infectionist and the cardiac surgeon. METHODS: We undertook a retrospective, descriptive study, spanning over a period of five years (from January 1st, 2007 to December 31st, 2012), on 100 @entity1 who underwent surgery for native @entity340 in our unit. RESULTS: The @entity1 ' age varied between 13 and 77 years (with a mean of 54 years), of which 85 were males (85%). The main microorganisms responsible for @entity166 were: Streptococcus @entity5645 . (21 cases - 21%), Staphylococcus @entity5645 . (15 cases - 15%), and Enterococcus @entity5645 . (9 cases - 9%). The potential source of @entity281 was identified in 26 @entity1 (26%), with most cases being in the dental area (16 cases - 16%). The lesions caused by @entity166 were situated in the left heart in 96 @entity1 (96%), mostly on the aortic valve (50 cases - 50%). In most cases (82%) we found preexisting endocardial lesions which predisposed to the development of @entity166 , most of them being @entity340 (38 cases - 38%). We performed the following surgical procedures: surgery on a single valve - aortic valve replacement (40 cases), mitral valve replacement (19 cases), @entity339 (1 case), surgery on more than one valve - mitral and aortic valve replacement (20 cases), aortic and tricuspid valve replacement (1 case), aortic valve replacement with a mechanical valve associated with @entity339 (5 cases), aortic valve replacement with a biological valve associated with @entity339 (2 cases), and mitral valve replacement with a mechanical valve combined with De Vega procedure on the tricuspid valve (1 case). In 5 @entity1 (5%) the bacteriological examination of valve pieces excised during surgery was positive. In 3 cases it matched the germ identified in the hemocultures, and in 2 cases it evidenced another bacterium. CONCLUSION: The overall mortality of 5% is well between the limits presented in literature, being higher (30%) in @entity1 who required emergency surgery. For the @entity1 who return into our clinic with @entity340 , the mortality after surgery was even higher (50%).

title: Surgical outcomes in native XXXX : the experience of the Cardiovascular Surgery Department - Cluj-Napoca Heart Institute.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral valve repair']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['prosthetic valve endocarditis', 'degenerative valvular lesions', 'valve infectious endocarditis']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['IE', 'infectious endocarditis']

answer: @entity340 :: (MESH:D006349,Disease) :: ['valve infectious endocarditis']


abstract: OBJECTIVE: @entity5 constitutes a major health issue in developing countries, representing the leading cause of @entity204 . Quantitative assessment by sophisticated diagnostic techniques is becoming increasingly important. Hence, a histochemical staining procedure and morphometric evaluation are used to obtain optimal information on the cellular events. The objective of present study is to assess the variation in cellular area, nuclear area, cellular diameter, nuclear diameter and nuclear/cytoplasmic ratio respectively in normal subjects, smokeless @entity286 users, (smokers, combination and @entity957 @entity1 . METHODS: Total 125 number of subjects were divided into five groups, each comprising 25 subjects of more than 40 years of age. These groups were: a. Normal, b. smokeless @entity286 users, c. smokers d. combination and e. @entity957 . Oral smears were obtained, stained with Feulgen stain and the cells were measured cytomorphometrically using Nikon imaging software. RESULTS: Our study showed a significant reduction in the cellular diameter, cellular area and increase in the nuclear diameter, nuclear area and nuclear/cytoplasmic ratio in @entity957 @entity1 as compared to @entity286 users and normal @entity1 . Significant changes were found in group I, II, III and IV when compared with group V but as such no significant intergroup variation was found in cellular and nuclear dimensions in smokers, smokeless @entity286 users, combination and control group. CONCLUSION: Quantitative parameters could be assessed by cytomorphometry. Cytomorphological changes in exfoliated squames could serve as a useful adjunct in the early diagnosis of @entity957 .

title: Distinct perturbations of XXXX @entity1 : A quantitative cytomorphometric analysis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Oral cancer']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['oral squamous cell carcinomas', 'oral squamous cell carcinoma']

answer: @entity957 :: (MESH:D002294,Disease) :: ['oral squamous cell carcinoma']


abstract: OBJECTIVE: @entity5 constitutes a major health issue in developing countries, representing the leading cause of @entity204 . Quantitative assessment by sophisticated diagnostic techniques is becoming increasingly important. Hence, a histochemical staining procedure and morphometric evaluation are used to obtain optimal information on the cellular events. The objective of present study is to assess the variation in cellular area, nuclear area, cellular diameter, nuclear diameter and nuclear/cytoplasmic ratio respectively in normal subjects, smokeless @entity286 users, (smokers, combination and @entity957 @entity1 . METHODS: Total 125 number of subjects were divided into five groups, each comprising 25 subjects of more than 40 years of age. These groups were: a. Normal, b. smokeless @entity286 users, c. smokers d. combination and e. @entity957 . Oral smears were obtained, stained with Feulgen stain and the cells were measured cytomorphometrically using Nikon imaging software. RESULTS: Our study showed a significant reduction in the cellular diameter, cellular area and increase in the nuclear diameter, nuclear area and nuclear/cytoplasmic ratio in @entity957 @entity1 as compared to @entity286 users and normal @entity1 . Significant changes were found in group I, II, III and IV when compared with group V but as such no significant intergroup variation was found in cellular and nuclear dimensions in smokers, smokeless @entity286 users, combination and control group. CONCLUSION: Quantitative parameters could be assessed by cytomorphometry. Cytomorphological changes in exfoliated squames could serve as a useful adjunct in the early diagnosis of @entity957 .

title: Distinct perturbations of @entity957 XXXX : A quantitative cytomorphometric analysis.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: AIM OF STUDY: To compare retrospectively the endoscopic treatment of @entity9007 by retrograde pancreatic drainage (ERPD), cystogastrostomy (ECG) or cystoduodenostomy ( @entity13115 ). @entity1 AND METHODS: Between 1987 and 1995 @entity9007 were successfully treated endoscopically in 30 @entity1 (13 @entity1 , 17 @entity1 ; mean age 49 [18-89] years): ERPD was accomplished through papillary insertion of 5-7 F prostheses into the cysts or pancreatic duct in 9 @entity1 ; ECG achieved drainage of cysts in the body or tail of the pancreas in 15 @entity1 , and @entity13115 for cysts in the head of the pancreas in three. Combined ERPD and ECG was necessary in three @entity1 . RESULTS: Significant @entity158 relief was achieved in all @entity1 , accompanied by increased appetite and weight. @entity432 or dislocation of the prosthesis required renewed endoscopic drainage in three @entity1 . The prostheses were removed, 2-12 months after implantation, when @entity158 relief had occurred and clinical as well as radiological findings had become normal. Recurrence 10-22 months after removal of the drain was observed in four @entity1 , of whom two had a successful second drainage procedure. Surgical intervention became necessary in three @entity1 because of inadequate drainage or (one case) @entity548 . CONCLUSION: These data indicate that endoscopic drainage of @entity9007 gives good results with a low complication rate and no deaths. The procedure is thus an alternative to the at present prevailing operative treatment.

title: [Endoscopic drainage of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity9007 :: ('MESH:D010192', 'Disease') :: ['pancreatic pseudocysts']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['Occlusion']

answer: @entity9007 :: (MESH:D010192,Disease) :: ['pancreatic pseudocysts']


abstract: UNASSIGNED: We previously discovered mediastinal fat-associated lymphoid clusters (MFALCs) as novel lymphoid clusters (LCs) associated with mediastinal fat tissue (MFT) in healthy @entity19 . However, no data about their morphology in immune-associated disease conditions, and their relationship with @entity358 , is available to date. In the present study, we compared the morphological features of MFALCs in 4-month-old male @entity19 @entity792 (MRL/MpJ-lpr @entity19 and BXSB/MpJ-Yaa @entity19 ) with those of the corresponding control strains (MRL/MpJ and BXSB/MpJ, respectively). In addition, we analyzed their correlation with @entity358 . Furthermore, immunohistochemistry for @entity5168 , @entity8236 , @entity9271 , @entity8320 , and @entity1603 was performed to detect T- and B-cells, macrophages, granulocytes, and proliferating cells, respectively. The spleen/body weight ratios and anti-dsDNA autoantibody titers were found to be significantly higher in the autoimmune models than in the control strains. Furthermore, the autoimmune model presented prominent MFALCs, with a significantly greater ratio of LC area to total MFT area, and more apparent diffused cellular infiltration into the lung lobes than the other studied strains. Higher numbers of T- and B-cells, macrophages, and proliferating cells, but fewer granulocytes, were observed in the autoimmune models than in the control strains. Interestingly, a significant positive Pearson's correlation between the size of the MFALCs and the density of @entity5168 -, @entity8236 -, and @entity9271 -positive cells in the lung was observed. Therefore, our data suggest a potentially important role for MFALCs in the progression of @entity358 . However, further investigation is required to clarify the pathological role of @entity358 , especially in @entity32 . This article is protected by copyright. All rights reserved.

title: Comparative analysis of mediastinal fat-associated lymphoid cluster development and lung cellular infiltration in @entity19 XXXX and the corresponding normal control strains.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disorders']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['lung disease', 'lung infiltration', 'MFALCs in lung disease']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease models']

answer: @entity792 :: (MESH:D001327,Disease) :: ['autoimmune disease models']


abstract: UNASSIGNED: We previously discovered mediastinal fat-associated lymphoid clusters (MFALCs) as novel lymphoid clusters (LCs) associated with mediastinal fat tissue (MFT) in healthy @entity19 . However, no data about their morphology in immune-associated disease conditions, and their relationship with @entity358 , is available to date. In the present study, we compared the morphological features of MFALCs in 4-month-old male @entity19 @entity792 (MRL/MpJ-lpr @entity19 and BXSB/MpJ-Yaa @entity19 ) with those of the corresponding control strains (MRL/MpJ and BXSB/MpJ, respectively). In addition, we analyzed their correlation with @entity358 . Furthermore, immunohistochemistry for @entity5168 , @entity8236 , @entity9271 , @entity8320 , and @entity1603 was performed to detect T- and B-cells, macrophages, granulocytes, and proliferating cells, respectively. The spleen/body weight ratios and anti-dsDNA autoantibody titers were found to be significantly higher in the autoimmune models than in the control strains. Furthermore, the autoimmune model presented prominent MFALCs, with a significantly greater ratio of LC area to total MFT area, and more apparent diffused cellular infiltration into the lung lobes than the other studied strains. Higher numbers of T- and B-cells, macrophages, and proliferating cells, but fewer granulocytes, were observed in the autoimmune models than in the control strains. Interestingly, a significant positive Pearson's correlation between the size of the MFALCs and the density of @entity5168 -, @entity8236 -, and @entity9271 -positive cells in the lung was observed. Therefore, our data suggest a potentially important role for MFALCs in the progression of @entity358 . However, further investigation is required to clarify the pathological role of @entity358 , especially in @entity32 . This article is protected by copyright. All rights reserved.

title: Comparative analysis of mediastinal fat-associated lymphoid cluster development and lung cellular infiltration in XXXX @entity792 and the corresponding normal control strains.

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: Nucleotide-binding domain and @entity368 -rich repeat (NLR) proteins are a diverse family of pattern recognition receptors that are essential mediators of @entity32 and host defense in the gastrointestinal system. Recent studies have identified a subgroup of inflammasome forming NLRs that modulate the mucosal immune response during @entity29 ( @entity29 ) and @entity1960 associated @entity105 . To better elucidate the contribution of NLR family members in @entity29 and @entity5 , we conducted a retrospective analysis of gene expression metadata from @entity1 @entity1 . These data revealed that @entity71676 , an inflammasome forming NLR, was significantly dysregulated in @entity29 and @entity694 . To better characterize the function of @entity71676 in disease pathogenesis, we used @entity71677 (-/-) @entity19 in @entity1960 and @entity1960 -associated @entity5 models. In this paper, we report that @entity71676 attenuates @entity344 and @entity105 . @entity71677 (-/-) @entity19 demonstrated significant increases in morbidity, @entity32 , and @entity105 compared with wild-type animals. Similar to data previously reported for related inflammasome forming NLRs, the increased @entity32 and @entity5 burden was correlated with attenuated levels of @entity635 and @entity6026 . Further mechanistic studies using bone marrow reconstitution experiments revealed that the increased disease pathogenesis in the @entity71677 (-/-) @entity19 was associated with nonhematopoietic-derived cells and suggests that @entity71676 functions in the colon epithelial cell compartment to attenuate @entity105 . Taken together, these data identify @entity71676 as an essential mediator of the host immune response during @entity29 and @entity5 . These findings are consistent with a model whereby multiple NLR inflammasomes attenuate disease pathobiology through modulating @entity635 and @entity6026 levels in the colon.

title: The @entity71676 inflammasome attenuates @entity1960 and @entity1960 -associated XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity368 :: ('CHEBI:25017', 'Chemical') :: ['leucine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal inflammation']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['tumorigenesis']

answer: @entity105 :: (MESH:D063646,Disease) :: ['tumorigenesis']


abstract: Nucleotide-binding domain and @entity368 -rich repeat (NLR) proteins are a diverse family of pattern recognition receptors that are essential mediators of @entity32 and host defense in the gastrointestinal system. Recent studies have identified a subgroup of inflammasome forming NLRs that modulate the mucosal immune response during @entity29 ( @entity29 ) and @entity1960 associated @entity105 . To better elucidate the contribution of NLR family members in @entity29 and @entity5 , we conducted a retrospective analysis of gene expression metadata from @entity1 @entity1 . These data revealed that @entity71676 , an inflammasome forming NLR, was significantly dysregulated in @entity29 and @entity694 . To better characterize the function of @entity71676 in disease pathogenesis, we used @entity71677 (-/-) @entity19 in @entity1960 and @entity1960 -associated @entity5 models. In this paper, we report that @entity71676 attenuates @entity344 and @entity105 . @entity71677 (-/-) @entity19 demonstrated significant increases in morbidity, @entity32 , and @entity105 compared with wild-type animals. Similar to data previously reported for related inflammasome forming NLRs, the increased @entity32 and @entity5 burden was correlated with attenuated levels of @entity635 and @entity6026 . Further mechanistic studies using bone marrow reconstitution experiments revealed that the increased disease pathogenesis in the @entity71677 (-/-) @entity19 was associated with nonhematopoietic-derived cells and suggests that @entity71676 functions in the colon epithelial cell compartment to attenuate @entity105 . Taken together, these data identify @entity71676 as an essential mediator of the host immune response during @entity29 and @entity5 . These findings are consistent with a model whereby multiple NLR inflammasomes attenuate disease pathobiology through modulating @entity635 and @entity6026 levels in the colon.

title: The XXXX inflammasome attenuates @entity1960 and @entity1960 -associated @entity105 .

answer: @entity71676 :: (195046(Tax:10090),Gene) :: ['NLRP1']


abstract: Nucleotide-binding domain and @entity368 -rich repeat (NLR) proteins are a diverse family of pattern recognition receptors that are essential mediators of @entity32 and host defense in the gastrointestinal system. Recent studies have identified a subgroup of inflammasome forming NLRs that modulate the mucosal immune response during @entity29 ( @entity29 ) and @entity1960 associated @entity105 . To better elucidate the contribution of NLR family members in @entity29 and @entity5 , we conducted a retrospective analysis of gene expression metadata from @entity1 @entity1 . These data revealed that @entity71676 , an inflammasome forming NLR, was significantly dysregulated in @entity29 and @entity694 . To better characterize the function of @entity71676 in disease pathogenesis, we used @entity71677 (-/-) @entity19 in @entity1960 and @entity1960 -associated @entity5 models. In this paper, we report that @entity71676 attenuates @entity344 and @entity105 . @entity71677 (-/-) @entity19 demonstrated significant increases in morbidity, @entity32 , and @entity105 compared with wild-type animals. Similar to data previously reported for related inflammasome forming NLRs, the increased @entity32 and @entity5 burden was correlated with attenuated levels of @entity635 and @entity6026 . Further mechanistic studies using bone marrow reconstitution experiments revealed that the increased disease pathogenesis in the @entity71677 (-/-) @entity19 was associated with nonhematopoietic-derived cells and suggests that @entity71676 functions in the colon epithelial cell compartment to attenuate @entity105 . Taken together, these data identify @entity71676 as an essential mediator of the host immune response during @entity29 and @entity5 . These findings are consistent with a model whereby multiple NLR inflammasomes attenuate disease pathobiology through modulating @entity635 and @entity6026 levels in the colon.

title: The @entity71676 inflammasome attenuates XXXX and @entity1960 -associated @entity105 .

answer: @entity1960 :: (MESH:D003092,Disease) :: ['colitis']


abstract: Nucleotide-binding domain and @entity368 -rich repeat (NLR) proteins are a diverse family of pattern recognition receptors that are essential mediators of @entity32 and host defense in the gastrointestinal system. Recent studies have identified a subgroup of inflammasome forming NLRs that modulate the mucosal immune response during @entity29 ( @entity29 ) and @entity1960 associated @entity105 . To better elucidate the contribution of NLR family members in @entity29 and @entity5 , we conducted a retrospective analysis of gene expression metadata from @entity1 @entity1 . These data revealed that @entity71676 , an inflammasome forming NLR, was significantly dysregulated in @entity29 and @entity694 . To better characterize the function of @entity71676 in disease pathogenesis, we used @entity71677 (-/-) @entity19 in @entity1960 and @entity1960 -associated @entity5 models. In this paper, we report that @entity71676 attenuates @entity344 and @entity105 . @entity71677 (-/-) @entity19 demonstrated significant increases in morbidity, @entity32 , and @entity105 compared with wild-type animals. Similar to data previously reported for related inflammasome forming NLRs, the increased @entity32 and @entity5 burden was correlated with attenuated levels of @entity635 and @entity6026 . Further mechanistic studies using bone marrow reconstitution experiments revealed that the increased disease pathogenesis in the @entity71677 (-/-) @entity19 was associated with nonhematopoietic-derived cells and suggests that @entity71676 functions in the colon epithelial cell compartment to attenuate @entity105 . Taken together, these data identify @entity71676 as an essential mediator of the host immune response during @entity29 and @entity5 . These findings are consistent with a model whereby multiple NLR inflammasomes attenuate disease pathobiology through modulating @entity635 and @entity6026 levels in the colon.

title: The @entity71676 inflammasome attenuates @entity1960 and XXXX -associated @entity105 .

answer: @entity1960 :: (MESH:D003092,Disease) :: ['colitis']


abstract: OBJECTIVE: The aim of the study was to determine the effectiveness of hysteroscopic endomyometrial resection in the treatment of @entity931 . STUDY DESIGN: Eighty-six @entity1 with @entity931 underwent hysteroscopic endomyometrial resection between November 1990 and November 1993. The surgery was carried out under spinal anesthesia in 54 (64%) of the @entity1 . A standard resectoscope was used and the uterine cavity distended with 2.2% @entity2228 . The mean follow-up period was 22 months (range 4-39). RESULTS: No major complications occurred and no fluid overload was reported. One episode of uterine perforation, one of @entity5280 , five episodes of @entity10 and four of @entity15111 were recorded. Hysterectomy was performed in five cases. Follow-up information was available on 79 (92%) @entity1 . @entity2588 was achieved in 20 (25%) @entity1 and @entity1866 in 44 (56%) @entity1 . Only three (4%) @entity1 showed no improvement in menstrual flow. CONCLUSIONS: Hysteroscopic endomyometrial resection is a safe and effective mode of treatment for @entity931 in selected @entity1 .

title: Hysteroscopic endomyometrial resection for the treatment of XXXX --follow-up of 86 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['postspinal headache']

entities_list: @entity1866 :: ('MESH:D008599', 'Disease') :: ['hypomenorrhea']

entities_list: @entity5280 :: ('MESH:D034161', 'Disease') :: ['pelvic infection']

entities_list: @entity931 :: ('MESH:D008595', 'Disease') :: ['menorrhagia']

entities_list: @entity15111 :: ('MESH:D006409', 'Disease') :: ['hematometra']

entities_list: @entity2588 :: ('MESH:D000568', 'Disease') :: ['Amenorrhea']

answer: @entity931 :: (MESH:D008595,Disease) :: ['menorrhagia']


abstract: UNASSIGNED: @entity4653 ( @entity4653 ) proton therapy has many advantages over conventional radiotherapy, but its effectiveness for treating @entity5 remains questionable. Gating dose delivery to the breathing pattern is a well-developed method in conventional radiotherapy for mitigating @entity5 , but its clinical efficiency for @entity4653 proton therapy is not yet well documented. In this study, the dosimetric benefits and the treatment efficiency of beam gating for @entity4653 proton therapy has been comprehensively evaluated. A series of dedicated 4D dose calculations (4DDC) have been performed on 9 different 4DCT(MRI) liver data sets, which give realistic 4DCT extracting motion information from 4DMRI. The value of 4DCT(MRI) is its capability of providing not only @entity1 geometries and deformable breathing characteristics, but also includes variations in the breathing patterns between breathing cycles. In order to monitor target motion and derive a gating signal, we simulate time-resolved beams' eye view ( @entity1493 ) x-ray images as an online motion surrogate. 4DDCs have been performed using three amplitude-based gating window sizes (10/5/3   mm) with motion surrogates derived from either pre-implanted fiducial markers or the diaphragm. In addition, gating has also been simulated in combination with up to 19 times rescanning using either volumetric or layered approaches. The quality of the resulting 4DDC plans has been quantified in terms of the plan homogeneity index (HI), total treatment time and duty cycle. Results show that neither beam gating nor rescanning alone can fully retrieve the plan homogeneity of the static reference plan. Especially for variable breathing patterns, reductions of the effective duty cycle to as low as 10% have been observed with the smallest gating rescanning window (3   mm), implying that gating on its own for such cases would result in much longer treatment times. In addition, when rescanning is applied on its own, large differences between volumetric and layered rescanning have been observed as a function of increasing number of re-scans. However, once gating and rescanning is combined, HI to within 2% of the static plan could be achieved in the clinical target volume, with only moderately prolonged treatment times, irrespective of the rescanning strategy used. Moreover, these results are independent of the motion surrogate used. In conclusion, our results suggest image guided beam gating, combined with rescanning, is a feasible, effective and efficient motion mitigation approach for @entity96 treatments.

title: Improving 4D plan quality for XXXX treatments by combining online image guided beam gating with rescanning.

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['PBS-based liver tumour']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['mobile tumours', 'tumour-motion']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['Pencil beam scanned', 'PBS']

answer: @entity96 :: (MESH:D008113,Disease) :: ['PBS-based liver tumour']


abstract: PURPOSE: To evaluate outcomes of trabeculectomy bleb needle revision with @entity1487 augmentation performed in the operating theater. METHODS: Retrospective study of all @entity1 undergoing trabeculectomy bleb needle revisions in the operating theater performed by a single surgeon in a metropolitan hospital in Australia. A total of 51 needle revisions were performed on 33 eyes over a mean follow-up time of 1.81  1.56 years. RESULTS: A total of 29% achieved intraocular pressure (IOP)  <=20 mm Hg off all @entity726 medications, and an additional 39% achieved qualified success with the addition of @entity726 medications, giving overall success of 68%. Analyzing success rate for target IOP <=16 mm Hg, 24% achieved target off all @entity726 medications, 35% achieved qualified success with the addition of @entity726 medications, giving an overall success rate of 59%. There was a statistically significant improvement in IOP, as compared with preoperative levels, at all timepoints postoperatively (P<0.05). However, number of @entity726 medications remained unchanged (P>0.05) contributing to the high percentage of qualified successes. Visual acuity remained unchanged and there were no major @entity260 . The Kaplan-Meier survival shows a survival rate of 60% with IOP <=20 mm Hg and 40% for IOP <=16 mm Hg at 5 years. CONCLUSIONS: Trabeculectomy needle revision is a useful option for the management of elevated IOP in the presence of a failed or failing trabeculectomy bleb. However, as with trabeculectomy, there tends to be a failure rate over time. This often leads to reinstitution of @entity726 medications and/or further needle revisions to maintain IOPs at target level. The procedure itself is minimally invasive with an acceptable safety profile.

title: Outcomes: Trabeculectomy Bleb Needle Revision With XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5-Fluorouracil']